Excellent
Partially Aligned
Patient Risk:
Moderate
Summary
The AI-generated content is strongly aligned with the provided FDA labeling for alprazolam/XANAX regarding dependence and withdrawal reactions and, in the label assessment excerpt, correctly reflects the FDA warning about concomitant benzodiazepine-opioid use (including profound sedation, respiratory depression, coma, and death). Other statements in the list (e.g., indications and withdrawal timing/PAWS details) cannot be verified against the supplied label text because those specifics are not included in the provided excerpts.
Category Scores
Accurate Statements
Concomitant use of XANAX (alprazolam) with opioids may result in profound sedation, respiratory depression, coma, and death.
Supported by Warnings and Precautions (5.1) and Drug Interactions (7.1) in the supplied label excerpts.
Abrupt discontinuation or rapid dosage reduction of XANAX after continued use may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures).
Supported by Warnings and Precautions (5.3) and Drug Abuse and Dependence (9.3) in the supplied label excerpts.
To reduce the risk of withdrawal reactions, use a gradual taper to discontinue XANAX or reduce the dosage.
Supported by Dosage and Administration (2.3) and Warnings and Precautions (5.3) in the supplied label excerpts.
Unsupported Statements
Xanax (alprazolam) is a benzodiazepine used to treat anxiety disorders.
The provided label excerpts specify GAD in adults (and panic disorder), but the broader phrase 'anxiety disorders' is not explicitly stated in the supplied text.
Xanax (alprazolam) is a benzodiazepine used to treat insomnia.
Insomnia is not included in the provided indications (Section 1 excerpts).
Xanax withdrawal symptoms can last from several days to several weeks or even months.
The supplied excerpts discuss acute withdrawal reactions and life-threatening withdrawal (including seizures) but do not provide the specific duration/timeline ranges claimed.
The timeline of Xanax withdrawal symptoms varies depending on dosage, length of time used, individual's overall health.
The provided excerpts support that a gradual taper is used to reduce withdrawal risk and that abrupt discontinuation/rapid reduction can precipitate withdrawal, but they do not state these specific determinants of withdrawal timeline.
Common symptoms of Xanax withdrawal include anxiety, insomnia, tremors, sweating, and seizures.
The supplied excerpts explicitly mention seizures as an example of life-threatening acute withdrawal; they do not list the other symptoms (anxiety, insomnia, tremors, sweating) as 'common' withdrawal symptoms.
Acute withdrawal symptoms begin within 24 to 48 hours after the last dose.
The supplied excerpts do not provide the 24–48 hour timing for acute withdrawal onset.
Acute withdrawal symptoms can last for several days.
The supplied excerpts do not provide a specific duration for acute withdrawal symptoms.
Peak withdrawal symptoms usually occur between 48 to 72 hours after the last dose.
The supplied excerpts do not provide a 48–72 hour 'peak' timing.
Withdrawal symptoms can persist for several weeks or even months after the last dose.
The supplied excerpts do not provide this persistence timeline for withdrawal symptoms.
Post-acute withdrawal syndrome (PAWS) is a condition involving symptoms that can persist for several weeks or even months after the last dose.
The provided excerpts do not mention PAWS or this specific concept/timeline.
Post-acute withdrawal syndrome (PAWS) can involve symptoms such as anxiety, depression, and insomnia.
The provided excerpts do not mention PAWS or these specific symptom attributions.
Contradictions
High
AI Statement
Xanax (alprazolam) is a benzodiazepine used to treat insomnia.
Label Reference
Indications and Usage (Section 1 excerpt).
Important Omissions
For discontinuation, the label excerpt specifies a taper rate example ('no more than 0.5 mg every 3 days') and that some patients may be resistant; the AI list does not include these label-specific taper details.
Importance:
Moderate
The label excerpt includes specific contraindications (e.g., hypersensitivity and strong CYP3A inhibitors except ritonavir); these are not addressed in the AI list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The opioid–benzodiazepine warning is correctly reflected (high safety relevance). However, several other statements in the AI list are not supported by the provided label excerpts (e.g., insomnia as an indication; detailed withdrawal timing/symptom lists; PAWS), which could mislead interpretation of appropriate use and expected withdrawal course.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements (notably insomnia as an indication and detailed withdrawal timing/PAWS claims) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit statements to the specific indications and withdrawal information that are present in the supplied label excerpts (e.g., GAD and panic disorder indications; label-supported dependence/withdrawal warning and taper guidance), and avoid adding unsupported timing/symptom/PAWS details not contained in the provided labeling.